Cervomed (CRVO) Stock
Small healthcare company developing medical technologies and diagnostics. Here's the price, business snapshot, and what's worth knowing about Cervomed in November 2026.
CervoMed Inc (CRVO) is a small‑capitalisation healthcare company with a market capitalisation near $66.8m. Companies at this size often focus on developing medical technologies, diagnostics or therapies and may be in pre‑revenue or early commercial stages. Key investor considerations include regulatory and clinical milestones, cash runway and financing plans, intellectual property and any partnerships or licensing agreements that could accelerate growth. Small caps can offer meaningful upside if technical or commercial milestones are met, but they also carry elevated volatility, liquidity constraints and a higher risk of dilution. Values can rise and fall, and past performance is not a guide to the future. This summary is for general, educational purposes only and not personal financial advice — consult company filings, official disclosures and, if needed, a regulated financial adviser to assess suitability for your circumstances.
Cervomed (CRVO) Stock Forecast
Analyst price target, next 12 months
$14.00
+885.9% vs today's $1.42
Price range over the last 12 months
Close to its 12-month low
Analysts covering Cervomed have a consensus 12-month target of $14.00, above the current price of $1.42.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 3 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Cervomed Inc's stock due to its significant potential for price increase.
Financial Health
Cervomed Inc is generating modest revenue and cash flow, with stable value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Milestones Watch
Progress in clinical trials or regulatory approvals can shift prospects materially, though timelines can slip and outcomes remain uncertain.
Capital & Partnerships
Financing, partnerships or licensing deals can extend runway and validate technology, but may dilute shareholders or depend on complex negotiations.
Market & Competition
Adoption, reimbursement and competitive dynamics shape long‑term opportunity; small firms may face resource constraints and regulatory barriers.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
